November 12, 2021
As a result of the COVID-19 pandemic, biopharmaceutical and medical device sectors have increasingly catalyzed innovation and diversification. In this article, published in MedTech Intelligence, Nicholas J. Diamond and Jameyson Price discuss five key trends that may impact investment flows into 2022: (1) Investments in supply chain innovations will continue to increase, (2) Significant investments in digital health ventures will continue, if regulations remain flexible, (3) M&A deals expected to increase as companies continue to look towards consolidation of offers, (4) Drug pricing pressures may impact innovation, and (5) FDA action in the medical device and biopharmaceutical sectors will impact product innovation and market entry. Diamond and Price illustrate the extent at which innovation can be impacted by ongoing regulatory developments.
For more information, please contact the professional(s) listed below, or your regular Crowell & Moring contact.